Clene to Present at Upcoming May Conferences

Rhea-AI Summary

Clene (Nasdaq: CLNN) and its subsidiary Clene Nanomedicine, a late clinical-stage biopharmaceutical company, will be participating in three major investor conferences in May 2024.

The conferences include the Mizuho Neuroscience Summit on May 20-21, the Benchmark 2024 Healthcare House Call Virtual Conference on May 21-22, and the Virtual A.G.P. Healthcare Conference on May 22.

Clene focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS, Parkinson's disease, and multiple sclerosis. Its investigational therapy, CNM-Au8®, aims to enhance central nervous system cell survival by targeting mitochondrial function and reducing oxidative stress.

Positive

• Clene is participating in three major investor conferences in May 2024, increasing visibility and potential investor interest.
• The company is focused on treating high-impact neurodegenerative diseases such as ALS, Parkinson's disease, and multiple sclerosis.
• CNM-Au8® is a first-in-class investigational therapy with potential to significantly improve central nervous system health.

Negative

• There is no mention of new clinical data or financial updates which might indicate a lack of recent progress.
• The press release does not provide any immediate financial benefits or new partnerships, leaving investors without concrete short-term gains.

SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, today announced that it will participate in the following investor conferences in May.

Mizuho Neuroscience Summit 2024
Dates: May 20-21, 2024
Location: Boston Harbor Hotel, Boston, MA
Format: Panel Presentations and 1x1 meetings

Benchmark 2024 Healthcare House Call Virtual Conference
Dates: May 21-22, 2024
Location: Virtual
Format: 1x1 meetings

Virtual A.G.P. Healthcare Conference
Date: May 22, 2024
Location: Virtual
Format: 1x1 meetings

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Contacts:

Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310

Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856

FAQ

What conferences will Clene (CLNN) attend in May 2024?

Clene will attend the Mizuho Neuroscience Summit on May 20-21, the Benchmark 2024 Healthcare House Call Virtual Conference on May 21-22, and the Virtual A.G.P. Healthcare Conference on May 22.

What is Clene's focus in biopharmaceuticals?

Clene focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS, Parkinson's disease, and multiple sclerosis.

What is CNM-Au8®?

CNM-Au8® is an investigational first-in-class therapy aimed at improving central nervous system cell survival by targeting mitochondrial function and reducing oxidative stress.